Literature DB >> 30860833

Selective Inhibitors of Helicobacter pylori Methylthioadenosine Nucleosidase and Human Methylthioadenosine Phosphorylase.

Rajesh K Harijan1, Oskar Hoff2, Rodrigo G Ducati1, Ross S Firestone1, Brett M Hirsch1, Gary B Evans2, Vern L Schramm1, Peter C Tyler2.   

Abstract

Bacterial 5'-methylthioadenosine/ S-adenosylhomocysteine nucleosidase (MTAN) hydrolyzes adenine from its substrates to form S-methyl-5-thioribose and S-ribosyl-l-homocysteine. MTANs are involved in quorum sensing, menaquinone synthesis, and 5'-methylthioadenosine recycling to S-adenosylmethionine. Helicobacter pylori uses MTAN in its unusual menaquinone pathway, making H. pylori MTAN a target for antibiotic development. Human 5'-methylthioadenosine phosphorylase (MTAP), a reported anticancer target, catalyzes phosphorolysis of 5'-methylthioadenosine to salvage S-adenosylmethionine. Transition-state analogues designed for HpMTAN and MTAP show significant overlap in specificity. Fifteen unique transition-state analogues are described here and are used to explore inhibitor specificity. Several analogues of HpMTAN bind in the picomolar range while inhibiting human MTAP with orders of magnitude weaker affinity. Structural analysis of HpMTAN shows inhibitors extending through a hydrophobic channel to the protein surface. The more enclosed catalytic sites of human MTAP require the inhibitors to adopt a folded structure, displacing the phosphate nucleophile from the catalytic site.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30860833      PMCID: PMC6635953          DOI: 10.1021/acs.jmedchem.8b01642

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  49 in total

1.  MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.

Authors:  Gregory V Kryukov; Frederick H Wilson; Jason R Ruth; Joshiawa Paulk; Aviad Tsherniak; Sara E Marlow; Francisca Vazquez; Barbara A Weir; Mark E Fitzgerald; Minoru Tanaka; Craig M Bielski; Justin M Scott; Courtney Dennis; Glenn S Cowley; Jesse S Boehm; David E Root; Todd R Golub; Clary B Clish; James E Bradner; William C Hahn; Levi A Garraway
Journal:  Science       Date:  2016-02-11       Impact factor: 47.728

2.  Structural enzymology of Helicobacter pylori methylthioadenosine nucleosidase in the futalosine pathway.

Authors:  Robbert Q Kim; Wendy A Offen; Gideon J Davies; Keith A Stubbs
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2013-12-31

3.  Neutron structures of the Helicobacter pylori 5'-methylthioadenosine nucleosidase highlight proton sharing and protonation states.

Authors:  Michael T Banco; Vidhi Mishra; Andreas Ostermann; Tobias E Schrader; Gary B Evans; Andrey Kovalevsky; Donald R Ronning
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-16       Impact factor: 11.205

Review 4.  Marked for death: targeting epigenetic changes in cancer.

Authors:  Sophia Xiao Pfister; Alan Ashworth
Journal:  Nat Rev Drug Discov       Date:  2017-03-10       Impact factor: 84.694

5.  Transition state structure of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Escherichia coli and its similarity to transition state analogues.

Authors:  Vipender Singh; Jeffrey E Lee; Sara Núñez; P Lynne Howell; Vern L Schramm
Journal:  Biochemistry       Date:  2005-09-06       Impact factor: 3.162

6.  Transition-state analysis of S. pneumoniae 5'-methylthioadenosine nucleosidase.

Authors:  Vipender Singh; Vern L Schramm
Journal:  J Am Chem Soc       Date:  2007-02-14       Impact factor: 15.419

7.  Design and synthesis of potent "sulfur-free" transition state analogue inhibitors of 5'-methylthioadenosine nucleosidase and 5'-methylthioadenosine phosphorylase.

Authors:  Alistair I Longshaw; Florian Adanitsch; Jemy A Gutierrez; Gary B Evans; Peter C Tyler; Vern L Schramm
Journal:  J Med Chem       Date:  2010-09-23       Impact factor: 7.446

8.  Femtomolar transition state analogue inhibitors of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Escherichia coli.

Authors:  Vipender Singh; Gary B Evans; Dirk H Lenz; Jennifer M Mason; Keith Clinch; Simon Mee; Gavin F Painter; Peter C Tyler; Richard H Furneaux; Jeffrey E Lee; P Lynne Howell; Vern L Schramm
Journal:  J Biol Chem       Date:  2005-03-04       Impact factor: 5.157

9.  PHENIX: a comprehensive Python-based system for macromolecular structure solution.

Authors:  Paul D Adams; Pavel V Afonine; Gábor Bunkóczi; Vincent B Chen; Ian W Davis; Nathaniel Echols; Jeffrey J Headd; Li-Wei Hung; Gary J Kapral; Ralf W Grosse-Kunstleve; Airlie J McCoy; Nigel W Moriarty; Robert Oeffner; Randy J Read; David C Richardson; Jane S Richardson; Thomas C Terwilliger; Peter H Zwart
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-01-22

10.  Targeting the polyamine pathway with transition-state analogue inhibitors of 5'-methylthioadenosine phosphorylase.

Authors:  Gary B Evans; Richard H Furneaux; Vern L Schramm; Vipender Singh; Peter C Tyler
Journal:  J Med Chem       Date:  2004-06-03       Impact factor: 7.446

View more
  3 in total

1.  Evaluation of Novel Quorum Sensing Inhibitors Targeting Auto-Inducer 2 (AI-2) for the Control of Avian Pathogenic Escherichia coli Infections in Chickens.

Authors:  Yosra A Helmy; Dipak Kathayat; Loic Deblais; Vishal Srivastava; Gary Closs; Robert J Tokarski; Oluwatosin Ayinde; James R Fuchs; Gireesh Rajashekara
Journal:  Microbiol Spectr       Date:  2022-05-18

2.  Identification of immucillin analogue natural compounds to inhibit Helicobacter pylori MTAN through high throughput virtual screening and molecular dynamics simulation.

Authors:  Divya S Raj; Chidhambara Priya Dharshini Kottaisamy; Waheetha Hopper; Umamaheswari Sankaran
Journal:  In Silico Pharmacol       Date:  2021-03-11

Review 3.  Helicobacter pylori treatment in the post-antibiotics era-searching for new drug targets.

Authors:  Paula Roszczenko-Jasińska; Marta Ilona Wojtyś; Elżbieta K Jagusztyn-Krynicka
Journal:  Appl Microbiol Biotechnol       Date:  2020-10-14       Impact factor: 4.813

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.